Ranedis Pharmaceuticals is Drug Discovery in United States that focus on pharmaceutical formulations business. Founded in 2014. They cover business area such as developer, pharmaceutical formulation, rare and neglected disease, Histone deacetylase, HDAC, inhibitor, its ability, doctor, pharmaceutical company, treatment, metabolic disease.
2014
( 10 years old in 2024 )
Pharmaceutical Formulations
-
Rosetree Corporate Center, 1400 North Providence Road
Building 1, Suite 115S
Media, PA 19063
United States
Private
developerpharmaceutical formulationrare and neglected diseaseHistone deacetylaseHDACinhibitorits abilitydoctorpharmaceutical companytreatmentmetabolic disease
* We use standard office opening hours in near Ranedis Pharmaceuticals's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Ranedis Pharmaceuticals is Drug Discovery business from United States that founded in 2014 (10 years old in 2024), Ranedis Pharmaceuticals business is focusing on Pharmaceutical Formulations.
Ranedis Pharmaceuticals headquarter office and corporate office address is located in Rosetree Corporate Center, 1400 North Providence Road Building 1, Suite 115S Media, PA 19063 United States.
Ranedis Pharmaceuticals was founded in United States.
In 2024, Ranedis Pharmaceuticals is currently focus on pharmaceutical formulations sector.
Above is snippet of Google Trends for "pharmaceutical formulations" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Ranedis Pharmaceuticals, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
